Despite the initial skepticism, targeted therapies represent a new perspective in the treatment of cancer. Tyrosine kinases, and in particular receptor tyrosine kinases (RTKs), are considered ideal targets for this type of therapy. MET, the tyrosine kinase receptor for the Hepatocyte Growth Factor (HGF), has recently become a very interesting and studied target in oncology. In this review we discuss firstly 'why' the MET/HGF pathway can be considered a target in human tumors; secondly 'where' MET/HGF inhibition can be useful in cancer treatment and finally 'how' MET and HGF can be inhibited using either monoclonal antibodies or tyrosine kinase inhibitors. We also highlight some questions in the anti-MET/HGF targeted therapy field that are still waiting for an answer.

Targeting MET: why, where and how?

GHISO, ELENA;GIORDANO, Silvia
2013

Abstract

Despite the initial skepticism, targeted therapies represent a new perspective in the treatment of cancer. Tyrosine kinases, and in particular receptor tyrosine kinases (RTKs), are considered ideal targets for this type of therapy. MET, the tyrosine kinase receptor for the Hepatocyte Growth Factor (HGF), has recently become a very interesting and studied target in oncology. In this review we discuss firstly 'why' the MET/HGF pathway can be considered a target in human tumors; secondly 'where' MET/HGF inhibition can be useful in cancer treatment and finally 'how' MET and HGF can be inhibited using either monoclonal antibodies or tyrosine kinase inhibitors. We also highlight some questions in the anti-MET/HGF targeted therapy field that are still waiting for an answer.
13
4
511
518
http://www.sciencedirect.com/science/article/pii/S1471489213000787
CELL LUNG-CANCER; PAPILLARY RENAL-CARCINOMAS; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; SOMATIC MUTATIONS; C-MET; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; GASTRIC-CANCER; THERAPEUTIC TARGET
Ghiso E;Giordano S
File in questo prodotto:
File Dimensione Formato  
2013_Targeting MET.why, where and how.pdf

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.43 MB
Formato Adobe PDF
1.43 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/139886
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 37
social impact